Conclusion
In conclusion, mirabegron monotherapy improved the JJ stent-related
urinary symptoms, body pain, work performance, sexual matters,
additional problems, and general health scores. Further studies are
needed to clarify the role and mechanisms of mirabegron in the
management of SRS.
Competing interests: The authors declare that they have no
competing interests.
Endnotes: None
Acknowledgment: None
Funding source: Authors declare they did not receive any
funding or support for the present study.